Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.95
- Piotroski Score 3.00
- Grade Overweight
- Symbol (THRX)
- Company Theseus Pharmaceuticals, Inc.
- Price $4.07
- Changes Percentage (0.12%)
- Change $0.01
- Day Low $4.06
- Day High $4.07
- Year High $12.37
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
- Last Earnings 07/30/2015
- Ex-Dividend for 5/16 Dividend 09/08/2015
- Dividend Payable 09/30/2015
- Today N/A
- Next Earnings (Estimated) 03/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.34
- Trailing P/E Ratio -3.0335820895522
- Forward P/E Ratio -3.0335820895522
- P/E Growth -3.0335820895522
- Net Income $-47,080,000
